Protocol summary

Study aim
Evaluation of the occurrence, effect and side effects oFcyclophosfamid and rituximab in the tratment of children with NEPHROTIC SYNDROM resistance to STEROID
Design
102 patients with Steroid-Resistant Nephrotic Syndrome were randomly divided into two groups and each group received a drug, and in parallel, each group was examined.
Settings and conduct
Qom hazrat Masoomeh hospital
Participants/Inclusion and exclusion criteria
All pationts whit NEPHROTIC SYNDROM resistance to STEROID
Intervention groups
Patients with steroid resistant nephrotic syndrome were divided into two groups. The first group received cyclophosphamide and the second group received rituximab.
Main outcome variables
Frequent relapses; Steroid dose

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20170527034146N2
Registration date: 2019-02-18, 1397/11/29
Registration timing: retrospective

Last update: 2019-02-18, 1397/11/29
Update count: 0
Registration date
2019-02-18, 1397/11/29
Registrant information
Name
mohsen akhavansepahi
Name of organization / entity
Hazrat massomeh hospital
Country
Iran (Islamic Republic of)
Phone
+98 25 3665 1802
Email address
makhavan@muq.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2017-09-23, 1396/07/01
Expected recruitment end date
2018-09-23, 1397/07/01
Actual recruitment start date
2017-09-23, 1396/07/01
Actual recruitment end date
2018-09-23, 1397/07/01
Trial completion date
2018-09-23, 1397/07/01
Scientific title
Evaluation of the occurrence, effect and side effects oFcyclophosfamid and rituximab in the tratment of children with NEPHROTIC SYNDROM resistance to STEROID that referred to Hazrate Massumeh hospital .
Public title
Evaluation of the occurrence, effect and side effects oFcyclophosfamid and rituximab in the tratment of children with NEPHROTIC SYNDROM resistance to STEROID that referred to Hazrate Massumeh hospital .
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
َAll patient whit nephrotic syndrome resistance to steroid whit age 1-18 yr
Exclusion criteria:
All patient who do not have steroid-resistant Nephrotic Syndrome for example patient with steroids depended syndrome. All patient who did not accept treatment All patient who died All patient who did not follow up
Age
From 1 year old to 18 years old
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size: 102
Actual sample size reached: 51
Randomization (investigator's opinion)
Randomized
Randomization description
The simple random sampling method was used for the selected sample and was divided into two groups of intervention and control by simple randomized distribution method. The randomized random number tool is the unit of individual cadastre. The patients were divided into two equal groups, regardless of sex and age, and on the basis of resistant to steroid therapy.The intervention group, in addition to prednisolone, received Ritoximab, which received a cyclophosphamide drug control group
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of QOM University of Medical Sciences
Street address
EMAM STREET.
City
QOM
Province
Ghoum
Postal code
3719815532
Approval date
2017-09-05, 1396/06/14
Ethics committee reference number
IR.MUQ.REC.1396.77

Health conditions studied

1

Description of health condition studied
Nephrotic syndrome resistance to steroide
ICD-10 code
N04.8
ICD-10 code description
Nephrotic syndrome with other morphologic changes

Primary outcomes

1

Description
The frequency of relapse of the disease before and after taking the cyclofosfamide and ritoximab
Timepoint
Weekly
Method of measurement
Urin analysis of proteine

2

Description
Dosage of the prednisolon before and after taking the medication
Timepoint
weekly
Method of measurement
check liste

Secondary outcomes

1

Description
Number of relapses after receiving rutioxime and cyclolophosphamide.
Timepoint
weekly
Method of measurement
Urinalysis. Patient's disease

2

Description
Dosage of Steroids after receiving medication
Timepoint
weekly
Method of measurement
check liste

Intervention groups

1

Description
Intervention group:I ntervention group: In addition to prednisolone, ritoximab with 375 mg / m 2 / day was given intravenously and weekly for 4 weeks.
Category
Treatment - Drugs

2

Description
Control group: Control group: In addition to prednisolone, cyclosfamide dose of 2 mg per kg per day For three months
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
hazrat masoomeh hospital
Full name of responsible person
mohsen akhavan sepahi
Street address
Emam street
City
Qom
Province
Ghoum
Postal code
۳۷۱۹۸۱۵۵۳۲
Phone
+98 25 3665 1801
Email
makhavan@muq.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Hosein Saghafi
Street address
Ghadir Street
City
Qom
Province
Ghoum
Postal code
3719815532
Phone
+98 25 3665 1804
Fax
Email
Register@muq.ac.ir
Web page address
https://fa.irct.ir/user/trial/37066/update/sponsor
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ghoum University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

2

Sponsor
Name of organization / entity
Assistant research in Qom medical univercity
Full name of responsible person
Hosein Saghafi
Street address
Ghadir Street
City
Qom
Province
Ghoum
Postal code
۳۷۱۹۸۱۵۵۳۲
Phone
+98 25 3665 1801
Email
Register@muq.ac.ir
Web page address
https://fa.irct.ir/user/trial/37066/update/sponsor
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Assistant research in Qom medical univercity
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Mohsen Akhavan sepahi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Emam sereet
City
Qom
Province
Ghoum
Postal code
3719815532
Phone
+98 25 3665 1804
Email
makhavan@muq.ac.ir
Web page address
https://fa.irct.ir/user/trial/37066/update/public_queries_contact

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Mohsen Akhavan sepahi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Emam street
City
Qom
Province
Ghoum
Postal code
3719815532
Phone
+98 256651804
Email
makhavan@muq.ac.ir
Web page address
https://fa.irct.ir/user/trial/37066/update/scientific_queries_contact

Person responsible for updating data

Contact
Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Mohsen Akhavan sepahi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Emam street
City
Qom
Province
Ghoum
Postal code
00983719815532
Phone
+98 256651804
Email
makhavan@muq.ac.ir
Web page address
https://fa.irct.ir/user/trial/37066/update/data_updater_contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Some of the details, such as information about the original message or its lover, can be shared.
When the data will become available and for how long
Since 1399
To whom data/document is available
Researchers working in academia and academia
Under which criteria data/document could be used
Clinical analyzes and clinical findings
From where data/document is obtainable
Principal Principal Prose Mohsen Akhavan Sepahi. E-mail: makhavan@muq.ac.ir
What processes are involved for a request to access data/document
Apply by e-mail to Mohsen Akhavan Sepahi
Comments
Loading...